Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities ... subjective ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...

in patients with generalized myasthenia gravis (gMG) were presented during ... focusing on patients' subjective experience and daily function. These data showed that patients treated with ...

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia gravis The ME&MGopenTM study highlights the potential ...

Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0 ...

Descartes-08 represents a flagship advancement in Cartesian’s mission to transform the treatment landscape for autoimmune diseases, with this latest data reinforcing its potential as a safe and ...

Some patients have follow-up data extending to 128 weeks. 1 b. QMG (Quantitative Myasthenia Gravis) is a 13-item assessment by a clinician that quantifies MG disease severity. The total QMG score ...